Solid oral dosage forms
The range includes tablets, capsules made with powder or microgranules, and stick packs.
Source: LinkedIn company description · Retrieved October 13, 2026
INPHARMASCI is a French CDMO located near Valenciennes and joined the ATHENA group in early 2020.
INPHARMASCI specializes in developing and manufacturing pharmaceutical products in solid oral forms. ATHENA IPS offers clients product development, formulation and design, ingredient sourcing, and regulatory support.
Based on the company’s public LinkedIn information, supplied through RevenueBase.
The company serves clients in the pharmaceutical industry.
The range includes tablets, capsules made with powder or microgranules, and stick packs.
Source: LinkedIn company description · Retrieved October 13, 2026
The company provides industrial scale-up, custom manufacturing, analyses, stability studies, and packaging.
Source: LinkedIn company description · Retrieved October 13, 2026
Supported appearances on published RevenueBase lists, including available memberships beyond displayed rankings.
Positions describe ordering within each source list. See how lists are built ↗
Embeddable award for your website
RevenueBase prepared this profile from the company’s public LinkedIn information and RevenueBase company data. These source records were retrieved on October 13, 2026. AI helped summarize these sources, with a separate automated check against the source text completed on November 3, 2026. Directory positions use company-contact counts from separate saved list snapshots dated September 14, 2026, September 15, 2026, September 16, 2026, September 17, 2026, September 18, 2026, September 19, 2026, September 26, 2026, September 27, 2026, September 29, 2026, October 7, 2026, October 8, 2026, October 9, 2026, October 10, 2026 and October 11, 2026. How the company lists are built.
Share a correction, your relationship to the company, and supporting sources. Requests are reviewed before changes are published.
Explore more companies by name, headquarters and business focus.